首页> 外文期刊>Tumour biology : >CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer
【24h】

CXCR4, CXCL12 and the relative CXCL12-CXCR4 expression as prognostic factors in colon cancer

机译:CXCR4,CXCL12和相对CXCL12-CXCR4表达是结肠癌预后的因素

获取原文
获取原文并翻译 | 示例
       

摘要

The CXCL12-CXCR4 axis is proposed to mediate metastasis formation. In this study, we examined CXCL12, CXCR4 and the relative CXCL12-CXCR4 expression as prognostic factors in two cohorts of colon cancer patients. Immunohistochemistry (IHC) and in situ hybridization (ISH) were used to study CXCR4, CXCL12 and relative CXCL12-CXCR4 expression in tissue microarrays. Our study included totally 596 patients, 290 in cohort 1 and 306 in cohort 2. For tumour, node, metastasis (TNM) stage III, low nuclear expression of CXCR4 was a positive prognostic factor for 5-year disease-free survival (DFS) in cohort 1 (P = 0.007) and cohort 2 (P = 0.023). In multivariate analysis for stage III, nuclear expression of CXCR4 in cohort 1 was confirmed as a prognostic factor for DFS (hazard ratio (HR), 0.27; 95 % CI, 0.09 to 0.77). For TNM stage III, high cytoplasmic expression of CXCL12 was associated with better 5-year DFS in both cohorts (P = 0.006 and P = 0.006, respectively). We further validated the positive prognostic value of CXCL12 expression for 5-year DFS in stage III with ISH (P = 0.022). For TNM stage III, the relative CXCL12-CXCR4 expression (CXCL12 > CXCR4 vs CXCL12 = CXCR4 vs CXCL12 < CXCR4) was a prognostic factor for 5-year DFS in cohort 1 (92 % vs 46 % vs 31 %, respectively; P < 0.001) and cohort 2 (92 % vs 66 % vs 30 %, respectively; P = 0.006). In conclusion, CXCL12 and relative CXCL12-CXCR4 expression are independent prognostic factors for 5-year DFS in TNM stage III colon cancer.
机译:建议使用CXCL12-CXCR4轴来介导转移形成。在这项研究中,我们检查了两个结肠癌患者队列中的CXCL12,CXCR4和相对CXCL12-CXCR4表达作为预后因素。免疫组织化学(IHC)和原位杂交(ISH)用于研究组织芯片中的CXCR4,CXCL12和相对CXCL12-CXCR4表达。我们的研究共纳入596例患者,队列1中290例,队列2中306例。对于肿瘤,淋巴结转移(TNM)III期,CXCR4的低核表达是5年无病生存(DFS)的积极预后因素群组1(P = 0.007)和群组2(P = 0.023)。在III期的多变量分析中,队列1中CXCR4的核表达被确认为DFS的预后因素(危险比(HR)为0.27; 95%CI为0.09至0.77)。对于TNM III期,两个队列中CXCL12的高细胞质表达与较好的5年DFS相关(分别为P = 0.006和P = 0.006)。我们进一步验证了ISH在III期5年DFS中CXCL12表达的阳性预后价值(P = 0.022)。对于TNM III期,相对CXCL12-CXCR4表达(CXCL12> CXCR4 vs CXCL12 = CXCR4 vs CXCL12

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号